Flagship Harbor Advisors’s Amicus Therapeutics FOLD Stock Holding History

Flagship Harbor Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-200	Closed	-$2.85K	–	1238
2025 Q4	$2.85K	Buy	+200	New	+$1.97K	﹤0.01%	1776
2020 Q4	–	Sell	-200	Closed	-$2K	–	951
2020 Q3	$2K	Sell	200 -331	-62%	-$4.82K	﹤0.01%	1718
2020 Q2	$8K	Buy	531 +331	+166%	+$4.03K	﹤0.01%	1419
2020 Q1	$2K	Hold	200	–	–	﹤0.01%	1645
2019 Q4	$2K	Hold	200	–	–	﹤0.01%	1708
2019 Q3	$1K	Hold	200	–	–	﹤0.01%	1746
2019 Q2	$2K	Hold	200	–	–	﹤0.01%	1674
2019 Q1	$2K	Hold	200	–	–	﹤0.01%	1666
2018 Q4	$1K	Hold	200	–	–	﹤0.01%	1733
2018 Q3	$3K	Hold	200	–	–	﹤0.01%	1814
2018 Q2	$3K	Buy	+200	New	+$3.02K	﹤0.01%	1766

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Flagship Harbor Advisors's FOLD Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 200 shares — an estimated $2.85K sold.

Flagship Harbor Advisors first reported a position in FOLD in Q2 2018 and held it in 11 quarters. The position peaked at $8K in Q2 2020. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Flagship Harbor Advisors reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Flagship Harbor Advisors sold 200 Amicus Therapeutics shares in Q1 2026, an estimated $2.85K.
Flagship Harbor Advisors first reported a position in Amicus Therapeutics in Q2 2018 and held it in 11 quarters.
Flagship Harbor Advisors's Amicus Therapeutics position peaked at $8K in Q2 2020.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.